Current evidence strongly suggests that TAAR1 agonists could represent potential pharmacotherapy options for managing stress-related disorders, including depression, bipolar disorder, and anxiety disorders such as PTSD, offering hope for more effective and safer treatments in the realm of mental health. The gene discussed is TAAR1; the disease is depressive symptom measurement.